<DOC>
	<DOCNO>NCT00786409</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety HPV vaccine Gardasil young woman .</brief_summary>
	<brief_title>Immunogenicity Safety HPV Vaccine Gardasil Young Women</brief_title>
	<detailed_description>Female patient systemic lupus erythematosus ( SLE ) find high rate persistent HPV infection precancerous lesion compare healthy population . The HPV vaccine Gardasil find safe efficacious female age 9 26 year . There data immunogenicity safety Gardasil females SLE . Immune dysfunction relate SLE immunosuppression secondary treatment SLE might prevent patient SLE develop adequate immune response vaccine . Also , theoretically , vaccine might induce disease exacerbation production new autoantibody . The purpose study evaluate immunogenicity safety Gardasil effect autoantibody profile female SLE patient age 9-26 year</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age : 9 26 year age Gender : Female All patient must fulfill revised American College Rheumatology Classification Criteria SLE diagnosis . Current SLEDAI score â‰¤ 6 Written , witness informed consent and/or assent obtain subject subject 's parent ( 18 year age ) legally acceptable representative prior enrollment Acute exacerbation disease within past 30 day require increase corticosteroid dose , initiation new immunosuppressive medication , hospitalization Current SLEDAI score &gt; 6 Patients receive rituximab last 6 month , currently cyclophosphamide treatment History allergic disease reaction likely exacerbate component study vaccine Previous administration HPV vaccine</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Lupus</keyword>
</DOC>